Valuation: Anixa Biosciences, Inc.

Market Cap 117M 105M 97.18M 88.01M 164M 11.16B 166M 1.16B 463M 5.84B 440M 430M 18.54B P/E 2026 *
-10.8x
P/E 2027 * -10.6x
Enterprise Value 117M 105M 97.18M 88.01M 164M 11.16B 166M 1.16B 463M 5.84B 440M 430M 18.54B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.36%
Yield 2026 *
-
Yield 2027 * -
10-26 Anixa Biosciences, Inc. Completes Dosing Of Fifth Cohort In Its Ongoing Phase 1 Clinical Trial Evaluating Its Novel FSHR-Targeted CAR-T Therapy For Recurrent Ovarian Cancer CI
10-05 Anixa Biosciences, Inc. Announces Patient Exhibits Stable Disease 90 Days After Treatment In Phase 1 Trial Evaluating Lira-Cel CI
10-01 Anixa Biosciences, Inc. Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial CI
09-16 Anixa Biosciences, Inc. Announces Appointment of Carmen Guerra to Cancer Business Advisory Board CI
09-10 Anixa Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2026 CI
08-19 Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine RE
07-14 Anixa Biosciences, Inc. Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology CI
07-06 Anixa Biosciences Treats First Patient in Fifth Cohort of Phase 1 Clinical Trial for FSHR-Targeted CAR-T Therapy in Recurrent Ovarian Cancer CI
07-06 Anixa Biosciences Treats First Patient in Fifth Cohort of Ovarian Cancer CAR-T Clinical Trial MT
06-29 Anixa Biosciences Granted Korean Patent for Breast Cancer Vaccine MT
06-26 Anixa Biosciences Presents Final Phase 1 Data For Breast Cancer Vaccine And Positive Survival Observations From Ongoing Ovarian Cancer CAR-T Therapy Trial CI
06-11 Anixa Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2026 CI
06-01 Anixa Biosciences Says Canadian IP Office Issues Notice of Allowance for Patent Covering Ovarian Cancer Vaccine Technology MT
1 day+2.74%
1 week+25.75%
Current month+15.02%
1 month+21.22%
3 months-2.60%
6 months+13.47%
Current year+8.01%
1 week 2.68
Extreme 2.68
3.43
1 month 2.6
Extreme 2.6
3.43
Current year 2.32
Extreme 2.32
3.89
1 year 2.32
Extreme 2.32
5.46
3 years 2.07
Extreme 2.07
5.46
5 years 2.07
Extreme 2.07
6.45
10 years 0.6
Extreme 0.6001
8.09
Manager TitleAgeSince
Chief Executive Officer 61 07/07/2017
Director of Finance/CFO 59 01/11/2016
Corporate Officer/Principal 72 07/09/2021
Director TitleAgeSince
Chairman 61 01/08/2016
Chairman 81 01/07/1999
Director/Board Member 76 01/09/2018
Date Insider Type Main position Quantity % Market Cap. Importance
30/09/26 Buy

Chief Financial Officer

5,500 0.0162%
24/09/26 Buy

Director

5,000 0.0147%
24/09/26 Buy

Chief Executive Officer

7,000 0.0206%
Change 5-day change 1-year change 3-year change Capi.($)
+2.74%+25.75%-22.17%+10.86% 114M
+0.65%-3.56%+33.53%+60.50% 63.48B
+1.76%+2.10%+12.10%+81.21% 54.55B
-0.94%+0.77%+8.85%+100.19% 53.59B
+2.76%+4.18%+28.34%+55.07% 44.75B
+2.00%-2.90%+18.37%+119.04% 41.62B
+1.34%-3.98%+225.44%+914.08% 39.91B
+0.64%-3.85%+11.71%+45.57% 32.47B
+29.06%+48.65%+106.84%+92.73% 26.7B
+3.72%-7.45%+24.25%-2.99% 23.36B
Average +4.36%+1.86%+44.73%+147.63% 38.05B
Weighted average by Cap. +3.21%-0.28%+47.54%+161.42%

Financials

2026 *2027 *
Net sales - -
Net income -10.51M -9.43M -8.72M -7.9M -14.76M -1B -14.94M -104M -41.54M -524M -39.46M -38.62M -1.66B -11.58M -10.39M -9.61M -8.7M -16.26M -1.1B -16.46M -115M -45.76M -577M -43.47M -42.55M -1.83B
Net Debt - -
Projected Income Statement - Annual - Anixa Biosciences, Inc.
Logo Anixa Biosciences, Inc.
Anixa Biosciences, Inc. is a biotechnology company. The Company is developing therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics program consists of the development of liraltagene autoleucel (lira-cel), a chimeric endocrine receptor-T cell therapy, which is a novel form of chimeric antigen receptor-T cell (CAR-T) technology, initially focused on treating ovarian cancer, that is being developed of its subsidiary, Certainty Therapeutics, Inc. (Certainty). Its vaccine programs include the development of a vaccine against breast cancer, the development of a vaccine against ovarian cancer, and a vaccine discovery program utilizing the same mechanism of its breast and ovarian cancer vaccines to develop additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon and prostate. It is also developing a method to vaccinate women against breast cancer, focused on triple-negative breast cancer.
Employees
4
Date Price Change Volume
29/10/26 $3.370 +2.74% 251,528
27/10/26 $3.280 +11.95% 497,903
26/10/26 $2.930 -2.01% 135,638
23/10/26 $2.990 +7.55% 326,688
22/10/26 $2.780 +2.58% 156,811
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Anixa Biosciences, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.370USD
Average target price
9.667USD
Spread / Average Target
+186.84%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Anixa Biosciences, Inc.
  1. Stock Market
  2. Stocks
  3. ANIX Stock